Rhythm Pharmaceuticals
RYTMApprovedRhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
RYTM · Stock Price
Historical price data
AI Company Overview
Rhythm Pharmaceuticals specializes in developing precision medicines for rare diseases of obesity and metabolic dysfunction caused by genetic deficiencies in the melanocortin-4 (MC4) pathway. Their flagship product IMCIVREE represents the first FDA-approved therapy specifically for certain rare genetic obesities, addressing significant unmet medical needs. The company continues to expand the clinical utility of setmelanotide across additional rare obesity syndromes while building a robust pipeline of next-generation therapies.
Technology Platform
Melanocortin-4 (MC4) receptor pathway modulation platform focused on developing precision therapies for rare genetic obesities and metabolic disorders.
Pipeline
26| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Setmelanotide + Moxifloxacin + Oral Placebo + SC Placebo | Healthy | Approved | |
| Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | |
| Setmelanotide | Bardet-Biedl Syndrome | Phase 3 | |
| Setmelanotide + Placebo | Hypothalamic Obesity | Phase 3 | |
| Setmelanotide + Placebo | Bardet Biedl Syndrome (BBS) | Phase 3 |
FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
Rhythm holds a unique position as the leader in MC4 receptor pathway therapies for rare obesity with limited direct competition. The company's first-mover advantage and deep scientific expertise provide differentiation from broader obesity treatment approaches and traditional pharmaceutical companies.